NYSE:HAE

Stock Analysis Report

Executive Summary

Haemonetics Corporation, a healthcare company, provides hematology products and solutions.

Snowflake

Fundamentals

High growth potential with proven track record.


Similar Companies

Share Price & News

How has Haemonetics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

5.2%

NYSE:HAE

1.5%

US Medical Equipment

0.8%

US Market


1 Year Return

15.7%

NYSE:HAE

9.7%

US Medical Equipment

1.9%

US Market

HAE outperformed the Medical Equipment industry which returned 9.6% over the past year.

HAE outperformed the Market in United States of America which returned 2.1% over the past year.


Share holder returns

HAEIndustryMarket
7 Day5.2%1.5%0.8%
30 Day-8.3%0.7%3.4%
90 Day8.5%2.4%2.1%
1 Year15.7%15.7%10.6%9.7%4.2%1.9%
3 Year244.5%244.5%70.2%65.0%46.7%37.2%
5 Year272.6%272.6%136.0%109.1%62.3%44.5%

Price Volatility Vs. Market

How volatile is Haemonetics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Haemonetics undervalued based on future cash flows and its price relative to the stock market?

131.93x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

Haemonetics's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

Haemonetics's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

Haemonetics is overvalued based on earnings compared to the US Medical Equipment industry average.

Haemonetics is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

Haemonetics is poor value based on expected growth next year.


Price Based on Value of Assets

Haemonetics is overvalued based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Haemonetics expected to perform in the next 1 to 3 years based on estimates from 7 analysts?

28.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Haemonetics's revenue is expected to grow by 9.7% yearly, however this is not considered high growth (20% yearly).

Haemonetics's earnings are expected to grow significantly at over 20% yearly.

Haemonetics's revenue growth is expected to exceed the United States of America market average.

Haemonetics's earnings growth is expected to exceed the United States of America market average.

Haemonetics's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Haemonetics is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).


Next Steps

Past Performance

How has Haemonetics performed over the past 5 years?

16.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Haemonetics's year on year earnings growth rate has been positive over the past 5 years.

Haemonetics's 1-year earnings growth exceeds its 5-year average (115.8% vs 16.6%)

Haemonetics's earnings growth has exceeded the US Medical Equipment industry average in the past year (115.8% vs 28.9%).


Return on Equity

Haemonetics has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

Haemonetics used its assets less efficiently than the US Medical Equipment industry average last year based on Return on Assets.


Return on Capital Employed

Haemonetics has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is Haemonetics's financial position?


Financial Position Analysis

Haemonetics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Haemonetics's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Haemonetics's level of debt (75.3%) compared to net worth is high (greater than 40%).

The level of debt compared to net worth has increased over the past 5 years (52.9% vs 75.3% today).

Debt is well covered by operating cash flow (31.2%, greater than 20% of total debt).

Interest payments on debt are well covered by earnings (EBIT is 8.3x coverage).


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 1.4x debt.


Next Steps

Dividend

What is Haemonetics's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Haemonetics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Haemonetics's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Haemonetics has not reported any payouts.

Unable to verify if Haemonetics's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Haemonetics has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Haemonetics's salary, the management and board of directors tenure and is there insider trading?

2.5yrs

Average management tenure


CEO

Chris Simon (55yo)

3.3yrs

Tenure

US$8,550,810

Compensation

Mr. Christopher Simon, also known as Chris, has been the Chief Executive Officer and President of Haemonetics Corporation since May 16, 2016. He joined Haemonetics in May 2016. Mr. Simon served as a Senior ...


CEO Compensation Analysis

Chris's remuneration is about average for companies of similar size in United States of America.

Chris's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

2.5yrs

Average Tenure

51.5yo

Average Age

The tenure for the Haemonetics management team is about average.


Board Age and Tenure

3.3yrs

Average Tenure

67yo

Average Age

The tenure for the Haemonetics board of directors is about average.


Insider Trading

Haemonetics individual insiders have only sold shares in the past 3 months.


Recent Insider Transactions

SellUS$13,12409 Sep 19
Josep Llorens
EntityIndividual
Shares101
Max PriceUS$129.94
SellUS$6,990,92721 Aug 19
Christopher Simon
EntityIndividual
Role
Chief Executive Officer
CEO, President & Director
Shares50,869
Max PriceUS$137.43
SellUS$227,51812 Aug 19
Ronald Gelbman
EntityIndividual
Role
Lead Director
Lead Director
Shares1,696
Max PriceUS$134.15
SellUS$609,92402 Jul 19
Christopher Simon
EntityIndividual
Role
Chief Executive Officer
CEO, President & Director
Shares5,008
Max PriceUS$121.79
SellUS$4,26513 Jun 19
Dan Goldstein
EntityIndividual
Role
Chief Accounting Officer
Principal Accounting Officer
Shares39
Max PriceUS$109.37
SellUS$7,54713 Jun 19
Said Bolorforosh
EntityIndividual
Role
Chief Technology Officer
Executive VP & CTO
Shares69
Max PriceUS$109.37
SellUS$11,81213 Jun 19
Jacqueline Scanlan
EntityIndividual
Role
Head of Human Resources
Senior Vice President of Global Human Resources
Shares108
Max PriceUS$109.37
SellUS$25,26413 Jun 19
Michelle Basil
EntityIndividual
Role
Chief Legal Officer
Executive VP
Shares231
Max PriceUS$109.37
SellUS$20,78013 Jun 19
William Burke
EntityIndividual
Role
Chief Financial Officer
CFO & Executive VP
Shares190
Max PriceUS$109.37
SellUS$136,49413 Jun 19
Christopher Simon
EntityIndividual
Role
Chief Executive Officer
CEO, President & Director
Shares1,248
Max PriceUS$109.37
SellUS$8,06410 Jun 19
Dan Goldstein
EntityIndividual
Role
Chief Accounting Officer
Principal Accounting Officer
Shares78
Max PriceUS$103.38
SellUS$21,50310 Jun 19
Jacqueline Scanlan
EntityIndividual
Role
Head of Human Resources
Senior Vice President of Global Human Resources
Shares208
Max PriceUS$103.38
SellUS$239,54910 Jun 19
Michelle Basil
EntityIndividual
Role
Chief Legal Officer
Executive VP
Shares2,315
Max PriceUS$103.50
SellUS$42,48910 Jun 19
William Burke
EntityIndividual
Role
Chief Financial Officer
CFO & Executive VP
Shares411
Max PriceUS$103.38
SellUS$292,97910 Jun 19
Christopher Simon
EntityIndividual
Role
Chief Executive Officer
CEO, President & Director
Shares2,834
Max PriceUS$103.38
SellUS$2,426,30924 May 19
Christopher Simon
EntityIndividual
Role
Chief Executive Officer
CEO, President & Director
Shares24,412
Max PriceUS$99.39
SellUS$5,442,54715 May 19
Christopher Simon
EntityIndividual
Role
Chief Executive Officer
CEO, President & Director
Shares57,587
Max PriceUS$94.51
SellUS$18,54510 Apr 19
Dan Goldstein
EntityIndividual
Role
Chief Accounting Officer
Principal Accounting Officer
Shares210
Max PriceUS$88.31
SellUS$9,69411 Mar 19
Jacqueline Scanlan
EntityIndividual
Role
Head of Human Resources
Senior Vice President of Global Human Resources
Shares116
Max PriceUS$83.57
SellUS$32,67611 Mar 19
Michelle Basil
EntityIndividual
Role
Chief Legal Officer
Executive VP
Shares391
Max PriceUS$83.57
SellUS$445,97418 Dec 18
Ronald Gelbman
EntityIndividual
Role
Lead Director
Lead Director
Shares4,329
Max PriceUS$103.02
SellUS$208,53809 Nov 18
William Burke
EntityIndividual
Role
Chief Financial Officer
CFO & Executive VP
Shares1,824
Max PriceUS$114.33
SellUS$1,410,86909 Nov 18
Pedro Granadillo
EntityIndividual
Shares12,322
Max PriceUS$114.50
SellUS$79,21730 Oct 18
William Burke
EntityIndividual
Role
Chief Financial Officer
CFO & Executive VP
Shares779
Max PriceUS$101.69
SellUS$10,37230 Oct 18
Dan Goldstein
EntityIndividual
Role
Chief Accounting Officer
Principal Accounting Officer
Shares102
Max PriceUS$101.69

Ownership Breakdown


Management Team

  • Gerry Gould (65yo)

    Vice President of Investor Relations

    • Tenure: 8.1yrs
  • Michelle Basil (47yo)

    Executive VP

    • Tenure: 0yrs
    • Compensation: US$2.15m
  • Chris Simon (55yo)

    CEO, President & Director

    • Tenure: 3.3yrs
    • Compensation: US$8.55m
  • Kevin O'Kelly-Lynch (52yo)

    Senior Vice President of Global Business Services

    • Tenure: 2.4yrs
  • Jackie Scanlan (46yo)

    Senior Vice President of Global Human Resources

    • Tenure: 2.5yrs
    • Compensation: US$1.49m
  • Bill Burke (51yo)

    CFO & Executive VP

    • Tenure: 3.1yrs
    • Compensation: US$2.31m
  • Dan Goldstein (42yo)

    Principal Accounting Officer

    • Tenure: 3.4yrs
  • Ian Purdy

    Senior Vice President of Global Quality & Regulatory Affairs

    • Tenure: 2.5yrs
  • Frank Tan

    Senior Vice President of Corporate Development & Planning

    • Tenure: 2.3yrs
  • Said Bolorforosh (57yo)

    Executive VP & CTO

    • Tenure: 1.3yrs
    • Compensation: US$1.41m

Board Members

  • Robert Abernathy (65yo)

    Director

    • Tenure: 1.9yrs
    • Compensation: US$245.06k
  • Rich Meelia (70yo)

    Chairman

    • Tenure: 8.3yrs
    • Compensation: US$419.94k
  • Ron Gelbman (71yo)

    Lead Director

    • Tenure: 0yrs
    • Compensation: US$262.94k
  • Ellen Zane (67yo)

    Director

    • Tenure: 1.7yrs
    • Compensation: US$249.94k
  • Claire Pomeroy (64yo)

    Director

    • Tenure: 0.4yrs
  • Mark Kroll (67yo)

    Independent Director

    • Tenure: 13.7yrs
    • Compensation: US$245.06k
  • Cathy Burzik (69yo)

    Director

    • Tenure: 2.9yrs
    • Compensation: US$254.80k
  • Chris Simon (55yo)

    CEO, President & Director

    • Tenure: 3.3yrs
    • Compensation: US$8.55m
  • Charles Dockendorff (65yo)

    Independent Director

    • Tenure: 5.2yrs
    • Compensation: US$266.94k

Company Information

Haemonetics Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Haemonetics Corporation
  • Ticker: HAE
  • Exchange: NYSE
  • Founded: 1971
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$6.450b
  • Shares outstanding: 50.77m
  • Website: https://www.haemonetics.com

Number of Employees


Location

  • Haemonetics Corporation
  • 400 Wood Road
  • Braintree
  • Massachusetts
  • 2184
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
HAENYSE (New York Stock Exchange)YesCommon StockUSUSDMay 1991
HAZDB (Deutsche Boerse AG)YesCommon StockDEEURMay 1991

Biography

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. It operates through Japan, EMEA, North America Plasma, and All Other segments. The company offers automated plasma ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/17 23:36
End of Day Share Price2019/09/17 00:00
Earnings2019/06/29
Annual Earnings2019/03/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.